OBJECTIVE: To describe a natural history model for primary sclerosing cholangitis (PSC) that is based on routine clinical findings and test results and eliminates the need for liver biopsy. PATIENTS AND METHODS: Using the Cox proportional hazards analysis, we created a survival model based on 405 patients with PSC from 5 clinical centers. Independent validation of the model was undertaken by applying it to 124 patients who were not included in the model creation. RESULTS: Based on the multivariate analysis of 405 patients, a risk score was defined by the following formula: R = 0.03 (age [y]) + 0.54 loge (bilirubin [mg/dL]) + 0.54 loge (aspartate aminotransferase [U/L]) + 1.24 (variceal bleeding [0/1]) - 0.84 (albumin [g/dL]). The risk score was used to obtain survival estimates up to 4 years of follow-up. Application of this model to an independent group of 124 patients showed good correlation between estimated and actual survival. CONCLUSIONS: A new model to estimate patient survival in PSC includes more reproducible variables (age, bilirubin, albumin, aspartate aminotransferase, and history of variceal bleeding), has accuracy comparable to previous models, and obviates the need for a liver biopsy.
OBJECTIVE: To describe a natural history model for primary sclerosing cholangitis (PSC) that is based on routine clinical findings and test results and eliminates the need for liver biopsy. PATIENTS AND METHODS: Using the Cox proportional hazards analysis, we created a survival model based on 405 patients with PSC from 5 clinical centers. Independent validation of the model was undertaken by applying it to 124 patients who were not included in the model creation. RESULTS: Based on the multivariate analysis of 405 patients, a risk score was defined by the following formula: R = 0.03 (age [y]) + 0.54 loge (bilirubin [mg/dL]) + 0.54 loge (aspartate aminotransferase [U/L]) + 1.24 (variceal bleeding [0/1]) - 0.84 (albumin [g/dL]). The risk score was used to obtain survival estimates up to 4 years of follow-up. Application of this model to an independent group of 124 patients showed good correlation between estimated and actual survival. CONCLUSIONS: A new model to estimate patient survival in PSC includes more reproducible variables (age, bilirubin, albumin, aspartate aminotransferase, and history of variceal bleeding), has accuracy comparable to previous models, and obviates the need for a liver biopsy.
Authors: C Schwarze; B Terjung; P Lilienweiss; U Beuers; V Herzog; T Sauerbruch; U Spengler Journal: Clin Exp Immunol Date: 2003-08 Impact factor: 4.330
Authors: M H Imam; E Sinakos; A A Gossard; K V Kowdley; V A C Luketic; M Edwyn Harrison; T McCashland; A S Befeler; D Harnois; R Jorgensen; J Petz; J Keach; A C DeCook; F Enders; K D Lindor Journal: Aliment Pharmacol Ther Date: 2011-09-29 Impact factor: 8.171
Authors: Evangelos Kalaitzakis; Maria Benito de Valle; Monira Rahman; Björn Lindkvist; Einar Björnsson; Roger Chapman; Nick Kontodimopoulos Journal: Qual Life Res Date: 2015-10-15 Impact factor: 4.147
Authors: John E Eaton; Bogdan Dzyubak; Sudhakar K Venkatesh; Thomas C Smyrk; Gregory J Gores; Richard L Ehman; Nicholas F LaRusso; Andrea A Gossard; Konstantinos N Lazaridis Journal: J Gastroenterol Hepatol Date: 2016-06 Impact factor: 4.029
Authors: John E Eaton; Kevin M Nelson; Andrea A Gossard; Elizabeth J Carey; James H Tabibian; Keith D Lindor; Nicholas F LaRusso Journal: Scand J Gastroenterol Date: 2019-05-26 Impact factor: 2.423
Authors: Ashwin N Ananthakrishnan; Andrew Cagan; Vivian S Gainer; Su-Chun Cheng; Tianxi Cai; Peter Szolovits; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Isaac Kohane; Katherine P Liao Journal: J Crohns Colitis Date: 2014-02-19 Impact factor: 9.071